Table 3 Patients’ clinical characteristics and disease severity assessment

Duration of illness (years)^b

8 (5 - 9)

2– 14

Frequency of admissions due to exacerbations during last year^b

1.5 (1– 2)

1– 4

Pediatric Bronchiectasis severity index, n (%)

 Mild

 Moderate

 Severe

7 (23.3%)

18 (60%)

5 (16.7%)

mMRC dyspnea scale, n (%)

 Grade 0

 Grade 1

 Grade 2

 Grade 3

13 (43.3%)

12 (40%)

4 (13.3%)

1 (3.3%)

BMI for age (kg/m2)^a

14.87 ± 1.99

10.8– 18.6

BMI Z-score interpretation

 Normal

 Low

15 (50%)

15 (50%)

Modified Bhalla score^b

9.5 (5– 14)

5– 20

Percentage of Lung volume affected by bronchiectasis in HRCT (%)^b

10 (7– 35)

5– 70

Spirometry results^a

 FVC (% predicted)

80.74 ± 19.46

22.6– 107

 FEV1 (% predicted)

70.94 ± 19.72

25.8– 109

 FEV1/FVC

91.36 ± 16.92

56– 115

 MMEF (% predicted)

64.32 ± 18.20

34– 92

PFT interpretation and severity grading (n=27)

 Normal

 Mild

 Moderate

 Severe

4 (14.8%)

7 (25.9%)

11 (40.7%)

5 (18.5%)

Total BAL cell count (c/mm3)^b

750 (275– 1200)

166– 16,000

Predominant BAL cell type

 Neutrophils

 Lymphocytes

23 (76.7%)

7 (23.3%)

Chronic airway infection

 No

 Yes

9 (30%)

21 (70%)

Type of organism, n(%)

 H. influenzae

 MRSA

 Pseudomonas aeruginosa

 Strept. Pneumoniae

11 (36.7%)

4 (13.3%)

4 (13.3%)

2 (6.7%)